Edmonton, Canada

Sreekanth Ramachandran

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Anacor Pharmaceuticals, Inc.. Active years: 2013.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 12.0

ph-index = 1

Forward Citations = 31(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Sreekanth Ramachandran: Innovator in Pharmaceutical Chemistry

Introduction

Sreekanth Ramachandran is a notable inventor based in Edmonton, Canada. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for medical applications. His work focuses on addressing critical health challenges, including bacterial infections.

Latest Patents

Sreekanth holds 1 patent for his invention titled "Trisubstituted boron-containing molecules." This invention primarily relates to 3,4,6-trisubstituted benzoxaborole compounds, which have shown promise in treating bacterial infections. His innovative approach in this area highlights the potential for new therapeutic options in combating resistant bacterial strains.

Career Highlights

Sreekanth is currently employed at Anacor Pharmaceuticals, Inc., where he continues to advance his research in pharmaceutical chemistry. His work at Anacor has positioned him as a key player in the development of new treatments that can significantly impact patient care.

Collaborations

Throughout his career, Sreekanth has collaborated with talented individuals such as Guofeng Jia and Yi Xia. These collaborations have fostered a productive research environment, leading to innovative solutions in the pharmaceutical industry.

Conclusion

Sreekanth Ramachandran's contributions to the field of pharmaceutical chemistry, particularly through his patented inventions, underscore his role as an influential inventor. His work not only advances scientific knowledge but also holds the potential to improve health outcomes for patients worldwide.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…